Author | Manfred Küpper and Rana Hallak |
Published in | Journal of the Syrian Clinical Laboratory Association, Volume 8, Issue 1&2, July 2016. |
Abstract | Background: Mycophenolic acid is a well established inhibitor of inosine-monophosphate-dehydrogenase (IMPDH) in immunosuppressive therapy. Adverse side effects require dose reduction in more than half of the patients, increasing the risk for acute rejection. Unlike for other immunosuppressants, measuring the trough level shows no relevant correlation to the risk of graft loss. Instead, we determined the residual IMPDH activity, aiming on suggesting trusted intervals for drug management in the context of dose-reduction. |
Link to read full paper |